Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Dec 1;180(12):1655-1663.
doi: 10.1001/jamainternmed.2020.5028.

Concordance Between Blood Pressure in the Systolic Blood Pressure Intervention Trial and in Routine Clinical Practice

Affiliations
Clinical Trial

Concordance Between Blood Pressure in the Systolic Blood Pressure Intervention Trial and in Routine Clinical Practice

Paul E Drawz et al. JAMA Intern Med. .

Abstract

Importance: There are concerns with translating results from the Systolic Blood Pressure Intervention Trial (SPRINT) into clinical practice because the standardized protocol used to measure blood pressure (BP) may not be consistently applied in routine clinical practice.

Objectives: To evaluate the concordance between BPs obtained in routine clinical practice and those obtained using the SPRINT protocol and whether concordance varied by target trial BP.

Design, setting, and participants: This observational prognostic study linking outpatient vital sign information from electronic health records (EHRs) with data from 49 of the 102 SPRINT sites was conducted from November 8, 2010, to August 20, 2015, among 3074 adults 50 years or older with hypertension without diabetes or a history of stroke. Statistical analysis was performed from May 21, 2019, to March 20, 2020.

Main outcomes and measures: Blood pressures measured in routine clinical practice and SPRINT.

Results: Participant-level EHR data was obtained for 3074 participants (2482 men [80.7%]; mean [SD] age, 68.5 [9.1] years) with 3 or more outpatient and trial BP measurements. In the period from the 6-month study visit to the end of the study intervention, the mean systolic BP (SBP) in the intensive treatment group from outpatient BP recorded in the EHR was 7.3 mm Hg higher (95% CI, 7.0-7.6 mm Hg) than BP measured at trial visits; the mean difference between BP recorded in the outpatient EHR and trial SBP was smaller for participants in the standard treatment group (4.6 mm Hg [95% CI, 4.4-4.9 mm Hg]). Bland-Altman analyses demonstrated low agreement between outpatient BP recorded in the EHR and trial BP, with wide agreement intervals ranging from approximately -30 mm Hg to 45 mm Hg in both treatment groups. In addition, the difference between BP recorded in the EHR and trial BP varied widely by site.

Conclusions and relevance: Outpatient BPs measured in routine clinical practice were generally higher than BP measurements taken in SPRINT, with greater mean SBP differences apparent in the intensive treatment group. There was a consistent high degree of heterogeneity between the BPs recorded in the EHR and trial BPs, with significant variability over time, between and within the participants, and across clinic sites. These results highlight the importance of proper BP measurement technique and an inability to apply 1 common correction factor (ie, approximately 10 mm Hg) to approximate research-quality BP estimates when BP is not measured appropriately in routine clinical practice.

Trial registration: SPRINT ClinicalTrials.gov Identifier: NCT01206062.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Drawz reported receiving grants from the National Institutes of Health (NIH) during the conduct of the study. Dr Agarwal reported receiving grants from Sprint EHR study during the conduct of the study. Dr Dwyer reported receiving grants from the NIH/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) during the conduct of the study; receiving personal fees from AstraZeneca and Sanofi; and serving as a consultant to AstraZeneca, Bayer, Sanofi, and CSL Behring outside the submitted work. Dr Horwitz reported receiving grants from the NIH/NIDDK/National Heart, Lung and Blood Institute (NHLBI) during the conduct of the study. Dr Lash reported receiving grants from the NIH during the conduct of the study. Dr McWilliams reported receiving grants from the NIH during the conduct of the study; receiving grants from Heineman Foundation outside the submitted work; and being a cofounder of iEnroll LLC. Dr Oparil reported receiving grants and nonfinancial support from the NIH/NHLBI during the conduct of the study; receiving personal fees from Preventric Diagnostics Inc and CinCor Pharma Inc outside the submitted work; serving as Editor-in-Chief, Current Hypertension Reports (term until 12/2020; Publisher, Springer Science Business Media LLC); and receiving an annual stipend of $5000 from Springer. Dr Rahbari-Oskoui reported receiving grants from the NIH during the conduct of the study; receiving grants and personal fees from Otsuka, Kadmon, and Sanofi; and receiving grants from Reata outside the submitted work. Dr Rahman reported receiving grants from the NIH during the conduct of the study; receiving grants from Bayer and Duke Clinical Research Institute; and receiving personal fees from Relypsa and Reata outside the submitted work. Dr Parkulo reported receiving grants from the NIH during the conduct of the study. Dr Rocco reported receiving grants from the NIH during the conduct of the study; receiving grants from Bayer, Boehringer Ingelheim, and GSK; and receiving personal fees from AbbVie, George Clinical, Beacon Bioscience, and Baxter outside the submitted work. Dr Soman reported receiving grant R01 HL136679 03 from the NHLBI during the conduct of the study. Dr Pajewski reported receiving grants from the NHLBI during the conduct of the study. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. CONSORT Diagram for the Systolic Blood Pressure Intervention Trial
BP indicates blood pressure; EHR, electronic health record; and SPB, systolic blood pressure.
Figure 2.
Figure 2.. Systolic Blood Pressure During Follow-up: Trial Measurements vs Outpatient Blood Pressures Extracted From the Electronic Health Record (EHR)
Estimates based on a linear mixed model with random intercepts for participant and clinic sites. Time since randomization was modeled using B-splines. Shaded areas denote 95% pointwise CIs.
Figure 3.
Figure 3.. Bland-Altman Plot Comparing Outpatient Systolic Blood Pressure (SBP) Readings From the Electronic Health Record (EHR) With Trial Measurements
Size of data points is proportional to the number of outpatient EHR measurements of SBP. Dashed lines indicate 95% limits of agreement. Overall: 1176 (38.8%) mean EHR – trial SBP difference between 5 and 15 mm Hg. Intensive treatment: 663 (43.6%) mean EHR – trial SBP difference between 5 and 15 mm Hg. Standard treatment: 513 (33.9%) mean EHR – trial SBP difference between 5 and 15 mm Hg.

Comment in

  • A Tale of 2 Blood Pressures.
    Dodson JA, Shimbo D. Dodson JA, et al. JAMA Intern Med. 2020 Dec 1;180(12):1663-1664. doi: 10.1001/jamainternmed.2020.5007. JAMA Intern Med. 2020. PMID: 33044492 No abstract available.

Similar articles

Cited by

References

    1. Wright JT Jr, Williamson JD, Whelton PK, et al. ; SPRINT Research Group . A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103-2116. doi:10.1056/NEJMoa1511939 - DOI - PMC - PubMed
    1. Williamson JD, Pajewski NM, Auchus AP, et al. ; SPRINT MIND Investigators for the SPRINT Research Group . Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA. 2019;321(6):553-561. doi:10.1001/jama.2018.21442 - DOI - PMC - PubMed
    1. Schiffrin EL, Calhoun DA, Flack JM. SPRINT proves that lower is better for nondiabetic high-risk patients, but at a price. Am J Hypertens. 2016;29(1):2-4. doi:10.1093/ajh/hpv190 - DOI - PubMed
    1. Agarwal R. Hypertension: rest before blood pressure measurement: a lesson from SPRINT. Nat Rev Nephrol. 2016;12(3):127-128. doi:10.1038/nrneph.2016.2 - DOI - PubMed
    1. Drawz PE, Ix JH. BP measurement in clinical practice: time to SPRINT to guideline-recommended protocols. J Am Soc Nephrol. 2018;29(2):383-388. doi:10.1681/ASN.2017070753 - DOI - PMC - PubMed

Publication types

Associated data